Neurocrine Biosciences Inc vs Abbvie Inc.
NBIX vs ABBV — side-by-side comparison from reported financials. NBIX leads 7, ABBV leads 4 of 11 comparable metrics.
Neurocrine Biosciences Inc
NBIX · Healthcare
$142.44+0.84%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | NBIX | ABBV |
|---|---|---|
| Price | $142.44 | $276.43 |
| Market cap | $14.5B | $488B |
| Revenue (TTM) | $3.37B | $64.4B |
| Revenue growth | +24.3% | +1.8% |
| Net margin | 20.9% | 9.8% |
| Free cash flow | $866M | $18.2B |
| Net cash (debt) | $1.01B | ($56.2B) |
| 1-year price return | +2.9% | +19.8% |
| P/E | 20.5 | 77.4 |
| P/E vs own history (cheap-side %) | 90% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 21% | 96% |
| Altman Z-score | 6.23 | 2.33 |
| CV checks passed | 10 of 10 | 9 of 10 |
| Employees | 2,500 | 57,000 |
Full résumé-style profiles: NBIX CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.